-
公开(公告)号：EP3231867A1
公开(公告)日：2017-10-18
申请号：EP15867698.1
申请日：2015-12-08
发明人： SATO, Noriyuki , TORIGOE, Toshihiko , HIROHASHI, Yoshihiko , KANASEKI, Takayuki , MIYAMOTO, Sho , KOCHIN, Vitaly , GOTO, Masashi
IPC分类号： C12N15/09 , A61K39/00 , A61K48/00 , A61P35/00 , C07K7/06 , C07K16/30 , C12Q1/68 , G01N33/15 , G01N33/50 , G01N33/574
CPC分类号： A61K39/0011 , A61K39/00 , A61K48/00 , A61K2039/572 , C07K7/06 , C07K16/2833 , C07K16/30 , C07K2317/34 , C12N5/0638 , C12N15/09 , C12Q1/68 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , G01N33/15 , G01N33/50 , G01N33/5088 , G01N33/574 , G01N2333/46
摘要： The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active ingredient; a method for screening the tumor antigen peptide; etc. To achieve the above-mentioned purpose, provided are: peptides represented by Y o -X o -Z o ; a polyepitope peptide consisting of a plurality of epitope peptides connected together, said polyepitope peptide containing at least one of the above-mentioned peptides as one of the epitope peptides; a polynucleotide encoding the aforementioned peptides and/or polyepitope peptide; a medicinal composition comprising the same as an active ingredient; a prophylactic and/or therapeutic agent for cancer characterized by inducing CTL; etc.
摘要翻译： 本发明的目的是提供：用于特异性检测癌症干细胞的检测剂; 肿瘤干细胞特异性表达的肿瘤抗原肽; 用于预防和/或治疗癌症的药物组合物，所述药物组合物包含上述肿瘤抗原肽作为活性成分; 筛选肿瘤抗原肽的方法; 为实现上述目的，提供了：由Yo-Xo-Zo代表的肽; 由多个连接在一起的表位肽组成的多表位肽，所述多表位肽含有至少一种上述肽作为表位肽之一; 编码上述肽和/或多表位肽的多核苷酸; 包含其作为活性成分的药物组合物; 特征在于诱导CTL的癌症的预防和/或治疗剂; 等等
-
公开(公告)号：EP3020806A1
公开(公告)日：2016-05-18
申请号：EP14823622.7
申请日：2014-07-11
发明人： MASUDA, Keiki , IGUCHI, Haruhisa , GOTO, Masashi , TORIGOE, Toshihiko , HIROHASHI, Yoshihiko , MORITA, Rena
CPC分类号： A61K39/0011 , A61K38/177 , A61K2039/55566 , A61K2039/57 , C07K14/4747 , C07K14/705 , C07K14/70539 , C07K16/2833 , C07K16/30 , C07K2317/32
摘要： Provided is a tumor antigen peptide and the like that is useful in the prevention and/or treatment of cancer. The present invention pertains to: a peptide comprising the amino acid sequence of sequence number 3, sequence number 4, sequence number 5, sequence number 6, or sequence number 11; a polyepitope peptide resulting from joining a plurality of epitope peptides and containing at least one of the aforementioned peptides as one epitope peptide; a polynucleotide coding for at least one of the polyepitope peptides or the peptides; a pharmaceutical composition containing the above as active ingredients; a cancer prevention and/or treatment agent characterized by inducing CTLs; and the like.
-
公开(公告)号：EP3949983A1
公开(公告)日：2022-02-09
申请号：EP20784003.4
申请日：2020-04-03
发明人： BAN, Hitoshi , TAKANASHI, Yosuke , GOTO, Masashi , SUGINOBE, Natsuko , IMAZAKI, Yusuke , IWATA, Yoshiko
IPC分类号： A61K39/00 , A61P37/04 , C07K14/47 , A61K9/107 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/34 , A61K47/44 , C07D239/49
摘要： The present invention relates to a compound useful as a vaccine adjuvant for cancer vaccine, a preparation process thereof, a pharmaceutical composition comprising the compound, and use of the compound as a vaccine adjuvant for cancer vaccine.
-
公开(公告)号：EP3461493A1
公开(公告)日：2019-04-03
申请号：EP18188307.5
申请日：2014-03-28
发明人： LI, Chiang Jia , BAN, Hitoshi , NISHIO, Yukihiro , GOTO, Masashi , NISHIHARA, Toshio , TAKANASHI, Yosuke
摘要： The present invention provides a compound represented by the formula (1):
wherein X a and Y a are each a single bond and the like,
cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7 - 30 amino acid residues,
R 1 is a hydrogen atom, a group represented by the formula (2):
wherein X b and Y b are each a single bond and the like,
cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7 - 30 amino acid residues, or cancer antigen peptide C, and
cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7 - 30 amino acid residues containing one cysteine residue,
or a salt thereof, and the like.-
公开(公告)号：EP2982681A1
公开(公告)日：2016-02-10
申请号：EP14775899.9
申请日：2014-03-28
发明人： LI, Chiang Jia , BAN, Hitoshi , NISHIO, Yukihiro , GOTO, Masashi , NISHIHARA, Toshio , TAKANASHI, Yosuke
CPC分类号： A61K39/0011 , A61K39/00 , A61K47/646 , A61K2039/55 , A61K2039/55511 , A61K2039/55566 , A61K2039/572 , A61K2039/64 , A61K2039/70 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/4748
摘要： The present invention provides a compound represented by the formula (1):
wherein X a and Y a are each a single bond and the like,
cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7 - 30 amino acid residues, R 1 is a hydrogen atom, a group represented by the formula (2):
wherein X b and Y b are each a single bond and the like,
cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7 - 30 amino acid residues, or cancer antigen peptide C, and
cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7 - 30 amino acid residues containing one cysteine residue,
or a salt thereof, and the like.摘要翻译： 本发明提供了由式（1）表示的化合物：其中Xa和Ya各自是单键等，癌抗原肽A是由7-30个氨基酸残基组成的MHC I类限制性WT1肽，R1 是氢原子，由式（2）表示的基团：其中Xb和Yb各自为单键等，癌抗原肽B具有与癌抗原肽A不同的序列，并且是MHC类 由7-30个氨基酸残基组成的I限制性WT1肽或癌抗原肽C和癌抗原肽C具有与癌抗原肽A不同的序列，并且是MHC I类限制性WT1肽或 由含有一个半胱氨酸残基的7-30个氨基酸残基组成的MHC II类限制性WT1肽，或其盐等。
-
6.发明公开CONJUGATE VACCINE USING TRIMMING FUNCTION OF ERAP1 审中-公开KONJUGATIMPFSTOFF MIT TRIMMFUNKTION VON ERAP1
公开(公告)号：EP2980097A1
公开(公告)日：2016-02-03
申请号：EP14773223.4
申请日：2014-03-28
CPC分类号： A61K39/0011 , A61K47/646 , A61K2039/572 , A61K2039/627 , C12N9/12 , C12Y207/10001
摘要： The present invention provides a compound represented by the formula (1):
wherein X a and Y a are each a single bond or the like, cancer antigen peptide A is an MHC class I-restricted cancer antigen peptide, and R 1 is a hydrogen atom; a group represented by the formula (2) :
wherein X b and Y b are each a single bond or the like, and cancer antigen peptide B is different from the cancer antigen peptide A and is an MHC class I or II-restricted cancer antigen peptide; a group represented by the formula (3):
wherein X c and Y c are each a single bond or the like, and cancer antigen peptide C is an MHC class II-restricted cancer antigen peptide; or cancer antigen peptide D, wherein the cancer antigen peptide D is an MHC class I or II-restricted cancer antigen peptide containing one cysteine residue,
or a salt thereof, for example.摘要翻译： 本发明提供由式（1）表示的化合物：其中X a和Y a各自为单键等，癌抗原肽A为MHC I类限制性癌抗原肽，R 1为氢 原子; 由式（2）表示的基团：其中X b和Y b各自为单键等，癌抗原肽B与癌抗原肽A不同，为MHC I类或II类限制性癌抗原 肽; 由式（3）表示的基团：其中X c和Y c各自为单键等，癌抗原肽C为MHC II类限制性癌抗原肽; 或癌抗原肽D，其中癌抗原肽D是含有一个半胱氨酸残基的MHC I类或II类限制性癌抗原肽或其盐。
-
7.发明公开
公开(公告)号：EP3549957A1
公开(公告)日：2019-10-09
申请号：EP17875568.2
申请日：2017-11-29
发明人： BAN, Hitoshi , GOTO, Masashi , TAKANASHI, Yosuke
摘要： The present application relates to WT1 helper peptides consisting of an amino acid sequence of 9 to 30 amino acid residues including a sequence: KLSHL as part thereof, and combinations of a WT1 helper peptide and a conjugate of cancer antigen peptides.
-
公开(公告)号：EP2982681B1
公开(公告)日：2018-08-22
申请号：EP14775899.9
申请日：2014-03-28
发明人： LI, Chiang Jia , BAN, Hitoshi , NISHIO, Yukihiro , GOTO, Masashi , NISHIHARA, Toshio , TAKANASHI, Yosuke
CPC分类号： A61K39/0011 , A61K39/00 , A61K47/646 , A61K2039/55 , A61K2039/55511 , A61K2039/55566 , A61K2039/572 , A61K2039/64 , A61K2039/70 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/4748
摘要： The present invention provides a compound represented by the formula (1): wherein X a and Y a are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7 - 30 amino acid residues, R 1 is a hydrogen atom, a group represented by the formula (2): wherein X b and Y b are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7 - 30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7 - 30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
-
公开(公告)号：EP3299028A1
公开(公告)日：2018-03-28
申请号：EP16796570.6
申请日：2016-05-19
IPC分类号： A61K39/00 , A61K38/00 , A61K39/39 , A61K39/395 , A61P35/00 , A61P35/02 , A61P43/00 , C07K14/82
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K39/39 , A61K39/395 , A61K39/3955 , A61K2039/505 , A61K2039/545 , A61P35/00 , A61P35/02 , C07K14/82
摘要： The invention relates to a combination use of a WT1 antigen peptide or a pharmaceutically acceptable salt thereof and an immunomodulator for treating or preventing cancer.
摘要翻译： 本发明涉及WT1抗原肽或其药学上可接受的盐和免疫调节剂用于治疗或预防癌症的组合应用。
-
公开(公告)号：EP3054010B1
公开(公告)日：2020-07-22
申请号：EP14850688.4
申请日：2014-10-03
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.019 秒)
